About this Research Topic
Sarcomas driven by a chromosomal fusion are a category of rare and neglected tumors. While the survival rate for many other tumors has improved significantly in recent decades, the overall survival rate of patients with fusion-driven sarcomas remains low. The need for effective therapies, especially for relapsed and metastatic disease, is enormous and pressing. Recent advances in next-generation sequencing have allowed for rapid and relatively inexpensive high-throughput analysis of these tumors, increasing our understanding of their genetic drivers and revealing novel therapeutic targets.
The lack of effective treatments for fusion-driven sarcomas, combined with the accessibility of high-throughput screening and advances in computational biology presents an opportunity to test new therapies in a highly impactful setting. The goal of this Research Topic is to collect descriptions of novel treatment strategies for fusion-driven sarcomas, including newly developed therapeutics and existing therapies that can be repurposed for these diseases. The goals of this collection are to inform readers of the current status of research on new targets for fusion-driven sarcomas and to generate rigorous pre-clinical evidence to enable translation of these treatments from the lab to the clinic.
This Research Topic will include articles discussing cellular therapies (CAR T cells, CAR NK cells), antibody-based therapies (bispecific antibodies, radioimmunotherapeutic antibodies, antibody-drug conjugates), small molecule inhibitors, and any other therapeutic modality that represents a novel treatment for this category of tumors. This includes novel therapeutics and those which have been proven in other cancer types and could be repurposed here. We would like to include a mix of original research and review articles.
Please note: studies consisting solely of bioinformatic investigation of publicly available genomic/transcriptomic/proteomic data do not fall within the scope of the section unless they are expanded and provide significant biological or mechanistic insight into the process being studied and will not be accepted as part of this Research Topic.
The lack of effective treatments for fusion-driven sarcomas, combined with the accessibility of high-throughput screening and advances in computational biology presents an opportunity to test new therapies in a highly impactful setting. The goal of this Research Topic is to collect descriptions of novel treatment strategies for fusion-driven sarcomas, including newly developed therapeutics and existing therapies that can be repurposed for these diseases. The goals of this collection are to inform readers of the current status of research on new targets for fusion-driven sarcomas and to generate rigorous pre-clinical evidence to enable translation of these treatments from the lab to the clinic.
This Research Topic will include articles discussing cellular therapies (CAR T cells, CAR NK cells), antibody-based therapies (bispecific antibodies, radioimmunotherapeutic antibodies, antibody-drug conjugates), small molecule inhibitors, and any other therapeutic modality that represents a novel treatment for this category of tumors. This includes novel therapeutics and those which have been proven in other cancer types and could be repurposed here. We would like to include a mix of original research and review articles.
Please note: studies consisting solely of bioinformatic investigation of publicly available genomic/transcriptomic/proteomic data do not fall within the scope of the section unless they are expanded and provide significant biological or mechanistic insight into the process being studied and will not be accepted as part of this Research Topic.
Keywords: Sarcoma, Genomic fusion, Chromosomal fusion, cellular therapies, antibody-based therapies
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
